All In Biotech

Drug Trial Radar · NCT06560593

A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics Characteristics of NTQ5082 Capsules Orally Administered in Healthy Volunteers in Single and Multiple Doses

Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

82

Planned (sponsor's estimate)

Start

Aug 2024

Primary completion

Dec 2024

Study completion Feb 2025

Sponsor

Sponsor type
Industry
First posted
Aug 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical trial to evaluate the safety, tolerability and PK/PD characteristics of NTQ5082 capsules orally administered in healthy subjects in single and multiple doses.

Conditions

  • Complement-mediated Hemolytic Diseases

Interventions

  • NTQ5082Drug

    single ascending dose, randomized, double-blind study,with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.

  • PlaceboDrug

    multiple ascending dose, randomized, double-blind study,with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the safety and tolerabilityTime frame: up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third hospital of Changsha

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.